FATE THERAPEUTICS INC
Data quality: 100%
FATE
NASDAQ
Manufacturing
Chemicals
$1.36
▲
$0.07
(5.43%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-41.27%
Growth
Revenue Growth (5Y)
-41.27%
Below sector avg (1.72%)
Revenue (1Y)-51.24%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-55.03%
Below sector avg (-54.68%)
ROIC-35.44%
Net Margin-2051.08%
Op. Margin-2222.45%
Safety
Debt / Equity
N/A
Current Ratio7.87
Interest CoverageN/A
Valuation
PE (TTM|NTM)
-1.08 | -1.23
Above sector avg (-1.50)
P/B Ratio0.63
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue declined -41.27% annually over 5 years
Negative free cash flow of -112.04 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 9.97%
Capital intensive — 89.57% of revenue goes to capex
Price History
Financial Trends
Analyst Price Target
9 analysts
Buy
+263.6%
upside to target
Current
$1.36
Consensus Target
$4.94
$2.00
Low
$8.00
High
Forecast
Forward P/E
-1.23
Forward EPS
-$1.05
Est. Revenue
5.79 M
Earnings Surprises
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -$0.28
·
Rev Est: 1.26 M
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -$0.32 | -$0.29 | -$0.27 | -$0.27 | — | — |
| Estimate | -$0.38 | -$0.34 | -$0.28 | -$0.27 | -$0.28 | -$0.29 |
| Surprise | +15.66% | +15.76% | +4.33% | +0.46% | — | — |
Growth
Rev 5Y: -41.27% · Earnings 1Y: N/A
Growth
Rev 5Y: -41.27% · Earnings 1Y: N/A| Revenue Growth (1Y) | -51.24% | Revenue Growth (3Y) | -67.66% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -41.27% | Earnings Growth (5Y) | N/A |
Profitability
ROE: -55.03% · Net Margin: -2051.08%
Profitability
ROE: -55.03% · Net Margin: -2051.08%| Revenue (TTM) | 6.65 M | Net Income (TTM) | -136.32 M |
| ROE | -55.03% | ROA | -38.11% |
| Gross Margin | N/A | Operating Margin | -2222.45% |
| Net Margin | -2051.08% | Free Cash Flow (TTM) | -112.04 M |
| ROIC | -35.44% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 7.87
Safety
D/E: N/A · Current: 7.87| Debt / Equity | N/A | Current Ratio | 7.87 |
| Interest Coverage | N/A | Asset Turnover | 0.02 |
| Working Capital | 193.14 M | Tangible Book Value | 234.07 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -1.08 · EV/EBITDA: N/A
Valuation
P/E: -1.08 · EV/EBITDA: N/A| P/E Ratio | -1.08 | Forward P/E | -1.23 |
| P/B Ratio | 0.63 | P/S Ratio | 22.22 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 25.49 | Fwd Earnings Yield | N/A |
| FCF Yield | -75.88% | ||
| Market Cap | 147.65 M | Enterprise Value | 107.03 M |
Per Share
EPS: -1.15 · FCF/Share: -0.96
Per Share
EPS: -1.15 · FCF/Share: -0.96| EPS (Diluted TTM) | -1.15 | Revenue / Share | 0.06 |
| FCF / Share | -0.96 | OCF / Share | -0.91 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 82.19% · CapEx/Rev: 89.57%
Efficiency
FCF Conv: 82.19% · CapEx/Rev: 89.57%| CapEx / Revenue | 89.57% | FCF Conversion | 82.19% |
| SBC-Adj. FCF | N/A | Growth Momentum | -9.97 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.65 M | 13.63 M | 63.53 M | 96.30 M | 55.85 M |
| Net Income | -136.32 M | -186.26 M | -160.93 M | -281.72 M | -212.15 M |
| EPS (Diluted) | -1.15 | -1.64 | -1.64 | -2.91 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -147.70 M | -210.28 M | -190.51 M | -308.39 M | -216.99 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 107.83 M | 135.00 M | 172.60 M | 320.45 M | 215.52 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 12.90 M | 18.96 M | 18.28 M | 13.76 M | 5.85 M |
| Interest Expense | — | — | — | — | 0.0 |
| Income Tax | 2,000.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 318.94 M | 440.69 M | 506.22 M | 705.56 M | 921.46 M |
| Total Liabilities | — | — | — | — | — |
| Shareholders' Equity | 207.18 M | 318.73 M | 368.42 M | 483.94 M | 678.84 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 46.63 M | 36.06 M | 41.87 M | 61.33 M | 133.58 M |
| Current Assets | 208.70 M | 291.91 M | 331.54 M | 502.07 M | 633.41 M |
| Current Liabilities | 36.07 M | 38.52 M | 39.09 M | 114.05 M | 81.28 M |
Peer Comparison
vs Manufacturing sector median (1605 peers)
Compared with similar companies in Manufacturing
Peer Comparison
vs Manufacturing sector median (1605 peers) Compared with similar companies in Manufacturing| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.1 | -1.5 |
| P/B | 0.6 | 1.6 |
| ROE % | -55.0 | -54.7 |
| Net Margin % | -2051.1 | -41.5 |
| Rev Growth 5Y % | -41.3 | 1.7 |
| D/E | — | 0.3 |
{"event":"ticker_viewed","properties":{"ticker":"FATE","listing_kind":"stock","pathname":"/stocks/fate","exchange":"NASDAQ","country":"US"}}